Palliative Care

The standing claim

Timing of specialist involvement is the primary lever. Brought in early enough, palliative care converts the final months from acute bed occupancy and futile intervention into time spent where the patient chooses to be. As of 2022 this is also, for the first time, a matter of law: an integrated care board must arrange palliative care provision (Health and Care Act 2022, s.21, amending the NHS Act 2006). The question this domain tracks is whether a discretionary duty becomes a resourced reality.

Where practice stands

The structural position changed in July 2022: palliative care was named explicitly, for the first time, in the list of services NHS commissioners are statutorily required to arrange (Health and Care Act 2022, s.21 → NHS Act 2006 s.3). But the duty is doubly qualified — to “such extent as [the board] considers necessary” and “as the board considers are appropriate” — so it is a duty to commission with discretion as to extent, and end-of-life charities note it has not yet translated into greater funding or equal access. NICE NG142 (End of life care for adults: service delivery) and the national Ambitions for Palliative and End of Life Care framework set the expected model. Identification remains a weak point: the community under-identification pattern is tracked in the pattern register.

What good looks like

“Good” is early, integrated specialist palliative care — and the evidence for earlier is consistent across designs. The landmark trial (Temel et al., 2010) showed that introducing specialist palliative care soon after diagnosis, alongside oncology, improved quality of life and mood, reduced aggressive end-of-life care, and was associated with longer survival. A nationwide register study found specialist contact more than 30 days before death was associated with markedly less acute hospitalisation in the final month (21% vs 38%) and far greater hospital-at-home use (Carpén et al., 2026). A systematic meta-review found advance care planning decreased hospital utilisation in line with patients’ preferences (Crooks et al., 2025).

But what delivers a preferred place of death is infrastructure, not paperwork. In a home palliative care cohort, 89% of patients with a documented home preference died at home — yet documentation itself was not independently associated with where people died (Reguillo et al., 2026): recording a preference is not the same as resourcing it. On delivery, a UK realist review identifies the components of effective community palliative rehabilitation — early referral, a layered specialist/generalist model, holistic assessment, services available across the whole journey rather than the last days only, and carer education as a formal part (Manson et al., 2025).

The exemplar is the model, chosen on outcomes: early, integrated specialist palliative care introduced well before the final weeks — the Temel/Carpén pattern — backed by a resourced infrastructure that can actually honour a stated preference.

The international benchmark is unusual for this publication: here the NHS is itself the exemplar. On the two serious cross-country measures of palliative-care quality the UK ranks first — 1st of 80 in the Economist Intelligence Unit’s 2015 Quality of Death Index, and still 1st in the 2021 expert assessment of the quality of death and dying, one of only six countries graded A (with Ireland, Taiwan, Australia, the Republic of Korea and Costa Rica; Finkelstein et al., 2021). The strength is structural — palliative care embedded in a universal system, a mature hospice movement, national policy. But the honest gap is place of death: among people over 65 dying with cancer across seven developed countries, 41.7% died in hospital in England versus 29.4% in the Netherlands (and 22.2% in the US), even though England spent the least of the seven on hospital care in the last six months of life (Bekelman et al., 2016). So the lesson to import is not a whole system but a specific lever — how the Netherlands enables more people to die at home — while Costa Rica’s grade-A performance stands as proof that this quality is reachable without high-income resourcing.

Through the lenses

This is the purest use-value domain in the publication. The measure is the lived quality of the time that remains and whether a person dies where they wished — not bed-days or activity units. McGilchrist’s caution is sharpest here: a good death cannot be decomposed into measurable variables; the advance-care-planning conversation is the intervention, and the DNACPR form is only the trace it leaves — exactly the illness-versus-disease distinction (Kleinman) and the phenomenological insistence that the patient’s experience is irreducible evidence. The VAT lens asks whether the final months added value on the patient’s own terms. Cross-domain, this meets acute frailty (D01) at the frailty–palliative boundary and OPAT (D05) at the question of what treatment is worth delivering at all near the end of life.

Confidence and limits

The statutory duty is firm in word but discretionary in extent. Temel is high-quality randomised evidence but cancer-specific (metastatic lung cancer) — extending it to non-cancer and frailty trajectories is a reasonable inference, not a demonstrated equivalence. Carpén is a national register study and Reguillo a single-centre cohort — observational, single-jurisdiction signals, not confirmation. On the international benchmark, two honest caveats: the quality-of-death indices measure expert-assessed system quality and perception, not population outcomes directly — and on the one hard outcome compared, place of death, England is mid-table rather than leading. The place-of-death figures are from 2010 cancer-decedent data, so treat the cross-country comparison as directional.

What we are watching

Whether the statutory duty translates into funding and genuinely equal access; community identification and registration of people in the last year of life; the palliative–OPAT interface; and whether England can close the place-of-death gap — enabling more people to die at home, as the Netherlands does — while protecting its top-ranked palliative-care quality.